News

Global Genes Starting Grant Cycle for RARE Meet-Ups

Global Genes is accepting grant applications to fund a series of U.S.-based RARE Meet-Ups for those affected by a rare disease, including cold-agglutinin disease (CAD), scheduled to occur from April to November. Grant applications are being accepted through the Global Genes Grant Portal until Feb. 4. Recipients…

Case Study: Secondary CAD Caused by Rare Cancer in Spleen

A case of secondary cold agglutinin disease (CAD) was triggered by a rare, undetected slow-growing type of immune cell cancer in the spleen. The case study, “Cold agglutinin syndrome secondary to splenic marginal zone lymphoma: a case report,” was published in the journal Hematology, Transfusion…

Patients Interviews Highlight Need for Better Outcome Measures

New patient-reported outcome measures capable of adequately capturing and assessing the impact of cold agglutinin disease (CAD) symptoms are needed, a study reported. Its scientists hope that by identifying relevant patient-reported outcome measures, clinicians and others involved in managing patients’ care can gain a better understanding of the concerns…

Sutimlimab Suppressed CAD Response in Heart Surgery Patient

Suppressing the pro-inflammatory complement pathway using sutimlimab, in addition to other measures, can help prevent red blood cell destruction in patients with cold agglutinin disease (CAD) undergoing major surgery, a recent case report suggests The study, “Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anaemia…

CAD Played Role in Acute Liver Failure of Elder Woman

Cold agglutinin disease (CAD) in an elder woman worsened an underlying autoimmune condition that subsequently led to acute liver failure, a case study reports. This case highlights a need for informed understanding of CAD and its associations with other autoimmune processes, and how it can lead to early interventions…